Hello Everyone,
I have been a reader of this community for the past three months since my father was diagnosed with advanced metastatic prostate cancer, but this is my first post. Please refer to my bio for more details.
My father (age 70) was diagnosed with advanced metastatic prostate cancer (PC) with a Gleason score of 4+5, which had metastasized to the bones and lymph nodes. His PSMA PET scan also showed sub-centimeter lesions in his liver. His PSA was not substantially high before treatment, measuring 5.57 ng/ml at diagnosis. His biopsy report indicated a majority adenocarcinoma component with focal neuroendocrine differentiation (negative for Chromogranin, positive for Synaptophysin (30%)).
Before starting treatment, he underwent genomic testing, which revealed that he is negative for any known genetic mutations and has a low tumour mutation burden.
Following the diagnosis, he was immediately started on dual hormone therapy (Lupron + Abiraterone). To further intensify the treatment, we also added Docetaxel-based chemotherapy to attack the cancer from all possible angles. Since the majority of his cancer cells are adenocarcinoma, the oncologist did not recommend platinum-based chemotherapy at this stage.
Before introducing Docetaxel, we measured his PSA response after 25 days of hormone therapy, and it had already dropped to 1.6 ng/ml. Now, after completing six infusions of Docetaxel in February 2025, his PSA has further reduced to 0.116 ng/ml.
While we are still waiting for his next PET scan report after his 6th infusion, I am feeling very anxious and wondering if anyone has been in a similar situation. I am particularly concerned about the liver lesion, even though his LFT results are within the normal range, as I have read that when prostate cancer reaches the liver, it can be more aggressive.
Would appreciate hearing from anyone with similar experiences or insights.